Interferon alfa-2a overdosage: Difference between revisions

Jump to navigation Jump to search
(Created page with "__NOTOC__ {{Interferon alfa-2a}} {{CMG}} ==Overdosage== There are no reports of overdosage, but repeated large doses of interferon can be associated with profound lethargy, [...")
 
Line 4: Line 4:


==Overdosage==
==Overdosage==
There are no reports of overdosage, but repeated large doses of interferon can be associated with profound lethargy, [[fatigue]], [[prostration]], and [[coma]]. Such patients should be hospitalized for observation and appropriate supportive treatment given.<ref>{{Cite web | last = | first =|title = http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/103964s5204lbl.pdf| url =http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/103964s5204lbl.pdf | publisher = |date = | accessdate = }}</ref>
There is limited experience with overdosage. The maximum dose received by any patient was 7 times the intended dose of PEGASYS (180 mcg/day for 7 days). There were no serious reactions attributed to overdosages. Weekly doses of up to 630 mcg have been administered to patients with cancer. Dose-limiting toxicities were fatigue, elevated liver enzymes, neutropenia, and thrombocytopenia. There is no specific antidote for PEGASYS. Hemodialysis and peritoneal dialysis are not effective.<ref>{{Cite web | last = | first =|title = http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/103964s5204lbl.pdf| url =http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/103964s5204lbl.pdf | publisher = |date = | accessdate = }}</ref>
 


==References==
==References==

Revision as of 01:12, 6 January 2014

Interferon alfa-2a
PEGASYS® FDA Package Insert
Description
Clinical Pharmacology
Microbiology
Indications and Usage
Contraindications
Warnings and Precautions
Adverse Reactions
Drug Interactions
Overdosage
Clinical Studies
Dosage and Administration
How Supplied
Labels and Packages

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overdosage

There is limited experience with overdosage. The maximum dose received by any patient was 7 times the intended dose of PEGASYS (180 mcg/day for 7 days). There were no serious reactions attributed to overdosages. Weekly doses of up to 630 mcg have been administered to patients with cancer. Dose-limiting toxicities were fatigue, elevated liver enzymes, neutropenia, and thrombocytopenia. There is no specific antidote for PEGASYS. Hemodialysis and peritoneal dialysis are not effective.[1]

References

  1. "http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/103964s5204lbl.pdf" (PDF). External link in |title= (help)

Adapted from the FDA Package Insert.